Skip to content
thispeptide

Ozempic Face: What Studies Measured and Whether It Is the Drug or the Weight Loss

"Ozempic face" is not a listed side effect. The first imaging study found about 7% of midface volume lost per 10 kg of body weight, and similar changes after bariatric surgery point to the weight loss itself.

Article type
Safety
Evidence on Semaglutide for weight
Large trials1 randomized trial of 1,000 or more people cited here for weight.
Sources
9
Reading
6 min
By Craig PalmerPublished

The phrase took off on social media as semaglutide grew popular, and it describes something plastic surgeons say they now see often: cheeks that flatten, skin that loosens, and a face that looks older than the scale suggests.

The useful question is whether the drug does something to the face, or whether the face simply follows the body when a lot of weight comes off quickly. The size of that loss is covered in how much weight you can lose on semaglutide.

What the label says, and what it does not

The Wegovy label never uses the term, and the only place it mentions the face is swelling during a serious allergic reaction [1]. It does describe the kind of weight semaglutide removes: the drug “lowers body weight with greater fat mass loss than lean mass loss.”

That sentence matters here, because the look people describe is a loss of the fat pads that give the face its shape. How much lean tissue goes with the fat is its own question, taken up in GLP-1 muscle loss.

The scale is large. In the STEP 1 trial, adults on semaglutide 2.4 mg weekly lost 14.9% of body weight over 68 weeks, or 15.3 kg on average, against 2.4% on placebo [2].

What has been measured

The first study to put numbers on the face during GLP-1 treatment, by its authors’ description, is small. Researchers at one academic center found 20 patients who happened to have head and neck CT or MRI scans both before and after starting a GLP-1 drug [3].

Over an average of 321 days on treatment, they lost an average of 11.0 kg. Median midface volume fell 9.0%, with the superficial fat pads falling 11.0% and the deep compartment 7.0%.

The authors estimate a loss of about 7% of midface volume for every 10 kg of weight lost. Superficial volume loss tracked weight loss (rho 0.590) while deep volume loss did not, a pattern consistent with the face shedding fat along with the rest of the body.

Studies that measured the face after weight loss
StudyWhoWhat was measuredFinding
Sharma 202520 patients on GLP-1 drugsMidface volume on CT or MRIMedian 9.0% loss; about 7% per 10 kg
Couto 20157 facelift patients after losing over 100 lbApparent age rated from photosLooked 5.1 years older than their age
Papoian 201514 bariatric surgery patientsPerceived age and attractivenessMixed on age; rated more attractive
Studies that measured the face after weight loss

Is it the drug or the weight loss?

The strongest clue is that the same complaint existed before these drugs. A facelift series found patients who had lost more than 100 pounds looked 5.1 years older than their actual age before surgery, against 1.2 years in a comparison group [4].

A bariatric surgery study asked survey respondents to rate before-and-after photos of 14 patients [5]. Five showed a significant shift in perceived age, three looking older and two less so, and patients were rated more attractive after the weight loss.

Commentators have reached the same place. A 2023 facial plastic surgery review attributes the look to rapid weight and fat loss depleting facial volume, leading to wrinkles and sagging skin [6].

A 2024 dermatology commentary frames it as an open question, whether this is a new adverse effect or a natural result of fast weight loss [7]. None of these sources shows an effect of semaglutide on facial tissue beyond the fat loss it causes.

How often do people raise it?

None of the sources here gives an incidence figure, because none counted it in a trial. A 2025 systematic review found 23 plastic surgery articles on these drugs and described the facial changes as resembling advanced aging, while noting the literature is limited by study bias [8].

A 2026 survey of 406 clinicians who treat cosmetic concerns reported a mean 137% rise in their patients taking GLP-1 drugs from 2023 to 2024 [9]. Midface volume loss and loose face and neck skin were the changes they linked most to these drugs.

Those clinicians rated hyaluronic acid filler the best option for facial concerns in an average of 47% of patients. The 2023 review also lists skin tightening and surgery [6]. These are practice patterns, not tested outcomes in GLP-1 patients.

Another change people notice during fast weight loss is covered in semaglutide hair loss. What is known about peptides applied to skin is in peptides for skin.

To compare prescribers, see the compounded semaglutide rankings.

Frequently asked questions

What is Ozempic face?
It is a media term for a hollow, sagging or older-looking face after fast weight loss on semaglutide or similar drugs. It is not an adverse reaction listed in the Wegovy label.
Does Ozempic face happen because of the drug or the weight loss?
The evidence points to the weight loss. The first imaging study found facial fat loss tracked body weight lost, and similar facial aging was described after bariatric surgery. None of these studies compared faces after equal weight loss by different methods.
How much facial volume do people lose on GLP-1 drugs?
In a study of 20 patients with CT or MRI scans before and after treatment, median midface volume fell 9.0% after an average weight loss of 11.0 kg. The authors estimate about 7% of midface volume per 10 kg lost.
How is Ozempic face treated?
In a 2026 survey of 406 clinicians, hyaluronic acid filler was rated the best option for facial concerns in an average of 47% of patients. A 2023 review also lists skin tightening and surgery. None of these has been tested in a trial of GLP-1 patients.

Sources

9 cited
  1. 1DailyMed, U.S. National Library of Medicine (2026). WEGOVY (semaglutide) injection; WEGOVY (semaglutide) tablets: prescribing information (revised 06/2026) DailyMed. Source
  2. 2Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine. PMID 33567185
  3. 3Sharma RK, Vittetoe KL, Barna AJ, Takkouche S, Varelas AN, Yang SF, et al. (2025). Radiographic Midfacial Volume Changes in Patients on GLP-1 Agonists Otolaryngology–Head and Neck Surgery. PMID 40407186
  4. 4Couto RA, Waltzman JT, Tadisina KK, Rueda S, Richards BG, Schleicher WF, et al. (2015). Objective Assessment of Facial Rejuvenation After Massive Weight Loss Aesthetic Plastic Surgery. PMID 26311559
  5. 5Papoian V, Mardirossian V, Hess DT, Spiegel JH (2015). Effects of Bariatric Surgery on Facial Features Archives of Plastic Surgery. PMID 26430627
  6. 6Humphrey CD, Lawrence AC (2023). Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons Facial Plastic Surgery. PMID 37541662
  7. 7Carboni A, Woessner S, Martini O, Marroquin NA, Waller J (2024). Natural Weight Loss or "Ozempic Face": Demystifying A Social Media Phenomenon Journal of Drugs in Dermatology. PMID 38206146
  8. 8Daneshgaran G, Shauly O, Gould DJ (2025). "Ozempic Face" in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions Aesthetic Surgery Journal Open Forum. PMID 40626110
  9. 9Fabi S, Yoo J, Kaufman-Janette J, Dayan S, Boyd C, Sangha S, et al. (2026). Aesthetic Concerns and Nonsurgical Treatment Trends in Patients With GLP-1 Agonist-Associated Weight Loss Dermatologic Surgery. PMID 42210883

More on weight